APOPTOSISKITS - M30-APOPTOSENSE^® ELISA

Catalog#: P10010     Patent number: 6296850     Package: 1 kit

For research use only, not for use in diagnostic procedures

M30‑Apoptosense^® is an enzyme‑linked immunosorbent assay (ELISA) for the quantitative detection of caspase‑cleaved cytokeratin‑18 (CK18Asp396‑NE: M30 neo‑epitope) levels in cytosolic cell extracts or the cell culture supernatants, human serum or plasma or other body fluids. The M30‑Apoptosense^® ELISA uses the M30 antibody which is specific to this CK18 cleavage site and does not react with viable or necrotic cells (Leers et al., 1999).

M30‑Apoptosense^® ELISA measures the accumulation of a caspase‑generated product resulting in an unmatched sensitivity thus allowing the tracing of apoptotic cells (e.g. originating from carcinomas) in patient sera (Ueno et al., 2003; Kramer et al., 2004). Due to this principle, the assay is ideally suited for high through‑put screening as well (Hägg et al. 2002).

M30‑Apoptosense^® ELISA is a unique tool for reliable and reproducible quantitative detection of apoptosis of CK18‑positive cells derived from simple epithelia in patient sera. All reagents are provided in a convenient ready‑for‑use format. The separable strips provide the flexibility for your experimental design!

BACKGROUND

The most frequent forms of cancer in humans arise from cells of simple epithelia and express cytokeratin 18 (CK18). The unique combination of high expression in most cancer cells, but not in non‑epithelial (lymphoid) cells, and the apoptosis specific cleavage by caspases makes CK18 an ideal marker for monitoring cancer cell apoptosis in human sera. Recent studies have indeed showed increased levels of caspase‑cleaved CK18 (CK18Asp396‑NE: M30 neo‑epitope) in sera from cancer patients subjected to different treatment regimen (Ueno et al., 2003; Bivén et al. 2003; Kramer et al., 2004)

M30‑Apoptosense^® is an ELISA based on the M30 monoclonal antibody (Leers et al., 1999) and therefore can be used for the quantitative detection of the M30 neo‑epitope (CK18Asp396‑NE) on CK18. As the M30 neo‑epitope is only exposed after caspase‑cleavage of CK18  (Hägg et al. 2002), it represents a specific marker of apoptosis in epithelial cells.

As the principle of the M30‑Apoptosense^® ELISA is to measure the accumulation of a caspase cleavage product rather than proteolytic activity itself, it represents an advantageous assay system for high through‑put screening (HTS) projects: it avoids the necessity to analyze multiple time‑points after the apoptotic stimulus making it cost‑effective as well (Hägg et al. 2002; Bivén et al. 2003; Hägg et al. 2004).

MORE INFORMATION

About the Distributor - DiaPharma Group, Inc.

About the Manufacturer - Peviva AB